Celentyx
- Company typePrivate
- Founded2007
- HeadquartersBirmingham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Celentyx firmographics
Firmographics- Name
- Celentyx
- Legal name
- Celentyx Ltd
- Website
- https://celentyx.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Celentyx industry classification
Industry- Product category
- Contract Research Services (Immunology CRO)
- NAICS
- Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Celentyx is headquartered
LocationHeadquarters
- HQ city
- Birmingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Celentyx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services: Bespoke assay services in human immunology delivered to pharmaceutical and biotech clients for drug discovery programs. Services include assay development, screening, and characterization studies performed on a fee-for-service basis.
- Bespoke Assay Development: Custom assay design and development services tailored to specific client drug discovery needs, from study design through optimization to interpretation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Celentyx product offering
Product offeringCore offering
Celentyx is a Contract Research Organization (CRO) that delivers bespoke immunology assay services for pharmaceutical and biotech drug discovery programs. The company uses patient and healthy donor primary cells and tissues to run in vitro assays spanning immuno-oncology, autoimmunity and inflammation, fibrosis, neuroinflammation, and COVID-19, supported by platform technologies including flow cytometry, CyTOF, Luminex, ELISA, high-content imaging, and 3D spheroid models. Services include candidate selection, medium-throughput screening, mechanism-of-action studies, target discovery, and proof-of-concept studies delivered on a fee-for-service basis.
Product overview
Celentyx is a Contract Research Organization (CRO) offering bespoke immunology assay services. The company provides a comprehensive portfolio of immune cell-based assay services organized across four therapeutic areas: Immuno-Oncology, Autoimmunity & Inflammation, Fibrosis, and Neuroinflammation. The core offerings include specialized cell-based assays (T cell exhaustion, T cell activation, tumour cell killing, NK cell assays, B cell assays, macrophage/monocyte assays, microglia assays, neutrophil assays, phagocytosis assays, fibroblast assays, regulatory T cell assays, suppression assays, TIL assays, antigen-specific assays, and haemolysis testing) combined with technology platforms (Flow Cytometry, CyTOF, Luminex, ELISA, ELISpot, ELLA, Cytokine Release Assays, Intracellular Cytokine Staining, Phosphoflow, Seahorse Metabolic Assays, and High-Content Imaging). Additional services include assays on patient cells and bespoke assay development. The company operates laboratories in Birmingham and Oxford, UK.
Differentiator
Problem solved
Functional benefit
Products and services
- Immuno-Oncology Assays In vitro assay services for immuno-oncology drug discovery using human primary immune cells, profiling T cell exhaustion, suppression, tumour cell killing, and dissociated human tumours. For pharmaceutical and biotech companies developing checkpoint inhibitors, bispecific antibodies, CAR-T cells, and other immuno-modulatory therapeutics.
- Autoimmunity & Inflammation Assays Assay services supporting therapeutic development for autoimmune and inflammatory diseases using human immune cells from healthy volunteers or patients, measuring proliferation, cytokine and chemokine release, cell migration, and phagocytosis. For pharmaceutical and biotech teams developing treatments for rheumatoid arthritis, psoriasis, SLE, and related conditions.
- Fibrosis Assays In vitro fibrosis drug validation services including Smad3 signalling, extracellular matrix accumulation, and collagen gel contraction assays using human fibroblasts. For pharmaceutical and biotech companies developing anti-fibrotic therapeutics for idiopathic pulmonary fibrosis, liver fibrosis, corneal scarring, and burns.
- Neuroinflammation Assays In vitro neuroinflammation drug validation using human cellular models to probe cytokine/biomarker release from astrocytes and microglia, plus electrophysiology, intracellular calcium measurements, cell chemotaxis, phagocytosis, and autoantibody binding. For pharmaceutical and biotech teams developing therapeutics for neurodegenerative and psychiatric disorders with neuroinflammatory components including Alzheimer's, Parkinson's, schizophrenia, and depression.
- COVID-19 Assays Cell-based ACE2/SARS-CoV-2 spike-binding high-throughput imaging assays for identification of small molecule or antibody inhibitors of spike binding. Developed and delivered in collaboration with the Universities of Birmingham and Warwick, with co-funding from Innovate UK.
- Bespoke Assay Development Customized assay design and development services for immunological and cell biological assays, covering background data review, study design, optimization, and interpretation. Delivered on a fee-for-service basis to pharmaceutical and biotech teams with unique or non-standard pre-clinical questions.
- Assays on Patient Cells Assay services performed on cells and tissues obtained from patient blood and tissue through strategic hospital relationships, compatible with flow cytometry, imaging, and multiplex biomarker quantification. Enables pharmaceutical and biotech clients to assess drug impact on patient cells with physiologically relevant samples, processed within hours of isolation.
Quantifiable outcome
- Over 2000 citations for CEO's research paper, indicating scientific leadership and credibility
Companies that use Celentyx
Customer profileSegments4 records
Ideal customer profiles4 records
Celentyx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Celentyx partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- Meiji Seika Kaisha, LtdminorCelentyx entered into agreement with Meiji Seika Kaisha in August 2009 to discover new development paths for Meiji drug candidates using Celentyx's Novel Clinical Indication Profiling™ technology.
- Hypha DiscoveryminorAnnounced Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery in July 2009.
- AMRIminorContinued collaboration with AMRI, including joint data presentations at British Pharmacological Society Winter Meeting 2008 and Serotonin Club Meeting 2008.
- Alfama IncminorCollaboration announced with Alfama Inc in October 2008.
- Schering-PloughminorCollaboration announced with Schering-Plough in January 2008 for immunology research services.
- ImmcellminorCollaboration demonstrating benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection, published January 2017.
- MRC Centre for Immune RegulationcoreClose association with MRC Centre for Immune Regulation at University of Birmingham enables access to world-leading immunology expertise and translational research capabilities.
- Centre for Translational Inflammation ResearchcoreStrategic relationship with Centre for Translational Inflammation Research supporting investigation of human immune system in health and disease.
- University of BirminghamcoreFounders from University of Birmingham; company benefits from neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine; collaborations for COVID-19 drug discovery with Universities of Birmingham and Warwick.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Celentyx competitors and assessment
Company assessmentBroad incumbents
- GenScript ProBio: Cell therapy and immunology services provider including cell-based assays and preclinical development — comparable to Celentyx in cell-based assay services for immuno-oncology and cell therapy sponsors.
- Eurofins Discovery: Large global CRO providing discovery and preclinical services including immunology, in vivo pharmacology, and cell-based assays — overlaps with Celentyx's preclinical immunology offerings but at much greater scale and breadth.
- Pharmaron: Integrated CRO with preclinical, biologics, and immunology services — competes for larger pharma R&D budgets including cell-based immunology assays adjacent to Celentyx's offering.
- Charles River Laboratories: Major preclinical CRO offering immunology, cell-based assays, and safety assessment; competes with Celentyx for immunology drug discovery budgets, though typically for larger enterprise engagements.
Regional players
- Svar Life Science: Nordic-based specialty CRO with strong immunology and cell-based assay offerings — comparable service portfolio to Celentyx though primarily serving European pharma/biotech.
Direct peers
- ReachBio Research Labs: Specialty CRO focused on human primary cell-based assays for hematology and immunology drug discovery — closely comparable niche positioning to Celentyx, serving pharma with bespoke cell-based assay services.
- BioAgilytix: Specialized bioanalytical and immunology-focused CRO offering immunoassays, cell-based assays, and biomarker services to pharma/biotech — directly comparable to Celentyx's human immunology assay services and therapeutic-area focus.
- ImmunXperts (Cenya): Immunology-focused CRO providing in vitro immunology assays including T cell, B cell, and innate immune cell assays using human cells — directly comparable service offering to Celentyx's assay menu.
Others
- Cellero (HemaCare): Provider of fresh and cryopreserved human primary immune cells for research and preclinical use — adjacent enabling supplier to Celentyx's patient-cell-based assay workflow.
Emerging players
- Proteros: Specialty CRO offering protein-based drug discovery and cell biology services, including immuno-oncology assays — partial overlap with Celentyx's immuno-oncology assay portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Celentyx social profiles
Digital presenceCelentyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celentyx leadership team
Management profileNumber of profiles
Profiles8 records
Celentyx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celentyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celentyx
What does Celentyx do?
Celentyx is a Contract Research Organization (CRO) that delivers bespoke immunology assay services for pharmaceutical and biotech drug discovery programs. The company uses patient and healthy donor primary cells and tissues to run in vitro assays spanning immuno-oncology, autoimmunity and inflammation, fibrosis, neuroinflammation, and COVID-19, supported by platform technologies including flow cytometry, CyTOF, Luminex, ELISA, high-content imaging, and 3D spheroid models. Services include candidate selection, medium-throughput screening, mechanism-of-action studies, target discovery, and proof-of-concept studies delivered on a fee-for-service basis.
Is Celentyx a public or private company?
Celentyx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Celentyx founded?
Celentyx was founded in 2007. It employs 11 to 50 people.
Where is Celentyx based?
Celentyx is headquartered in Birmingham, United Kingdom, in the Europe region.
How does Celentyx make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are bespoke Assay Development.
Who are Celentyx's main competitors?
Broad incumbents on record are GenScript ProBio, Eurofins Discovery, Pharmaron and Charles River Laboratories. Svar Life Science is listed as a regional player. Direct peers are ReachBio Research Labs, BioAgilytix and ImmunXperts (Cenya). Cellero (HemaCare) is listed as an others. Proteros is listed as an emerging player.
Does Celentyx have an API?
No public API is recorded for Celentyx.
What industry is Celentyx in?
Celentyx's product category is Contract Research Services (Immunology CRO). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54138 and its SIC code is 8731.